OBJECTIVES: Prostaglandin analogs (PGAs) are recommended as first-line therapy to lower intraocular pressure among glaucoma patients. Patients with lower rates of persistence could potentially have a higher risk of developing progressive visual loss. This study aims to compare persistence on latanoprostene bunod, latanoprost, bimatoprost, travoprost, and Beta Blockers, within a 12-month analysis period.

METHODS: Anonymized patient-level data for reimbursed drug transactions, from the IQVIA Canadian Private Drug Plan (PDP) and Ontario Drug Benefit (ODB) databases, was used to index patients on their first claim for specific products during a 12-month period. Patients were followed for 3, 6, and 12 months. Persistence was measured from index to first observed significant gap in therapy (days supplied of claim with an allowable grace period of 90 days) and output as a Kaplan-Meier curve.

RESULTS: From a cohort of 37,271 patients (latanoprostene bunod n = 1,315, bimatoprost n = 12,135, travoprost n = 5,136, latanoprost n = 9,864, Beta Blockers n = 7,592), those indexing on latanoprostene bunod demonstrate significantly higher persistence at 3, 6 and 12 months (62.28 %, 45.48 %, 32.40 % respectively, p<0.001) compared to bimatoprost (57.04 %, 41.34 %, 27.63 %, respectively), travoprost (49.38 %, 30.86 %, 17.00 %, respectively), and beta blockers (34.46 %, 18.48 %, 8.56 % respectively). Persistence among patients initiating on latanoprostene bunod is similar to those initiating all other PGAs combined (59.21 %, 43.65 %, 30.05 % at 3, 6 and 12 months, respectively).

CONCLUSIONS: In the Canadian population studied, persistence on latanoprostene bunod was better compared to other key PGAs and Beta Blockers. Strategies that support improved persistence and compliance with PGAs could prevent vision loss among patients.